Please use this identifier to cite or link to this item: http://hdl.handle.net/11189/5756
DC FieldValueLanguage
dc.contributor.authorPheiffer, Carmen-
dc.contributor.authorErasmus, Rajiv T-
dc.contributor.authorKengne, Andre Pascal-
dc.contributor.authorMatsha, Tandi Edith-
dc.date.accessioned2017-06-20T12:45:12Z-
dc.date.available2017-06-20T12:45:12Z-
dc.date.issued2016-
dc.identifier.urihttps://doi.org/10.1016/j.clinbiochem.2015.11.021-
dc.identifier.urihttp://hdl.handle.net/11189/5756-
dc.description.abstractObjective: Accumulating evidence supports the role of epigenetic modifications, and in particular DNA methylation and non-coding RNAs in the pathophysiology of type 2 diabetes. Alterations in methylation patterns within promoter regions are linked with aberrant transcription and pathological gene expression; however the role of methylation within non-promoter regions is not yet fully elucidated. Design and methods: We performed whole genome methylated DNA immunoprecipitation sequencing (MeDIP-Seq) in peripheral-blood-derived DNA from age–gender–body mass index (BMI)–ethnicity matched type 2 diabetic, pre-diabetic and non-diabetic individuals. Results: The density of methylation normalized to the average length of the promoter, intergenic and intragenic regions and to CpG count was 3.17, 9.80 and 0.09 for the promoter, intergenic and intragenic regions, respectively. Methylation within these regions varied according to glucose tolerance status and was associated with hypermethylation rather than hypomethylation. MicroRNA–DNA methylation peaks accounted for 4.8% of the total number of peaks detected. Differential DNA methylation of these microRNA peaks was observed during dysglycemia, with the promoter, intergenic and intragenic regions accounting for 2%, 95% and 3% respectively, of the differentially methylated microRNA peaks. Conclusion: Genome-wide DNA methylation varied according to glucose tolerance. Methylation within nonpromoter regions accounted for the majority of differentially methylated peaks identified, thus highlighting the importance of DNA methylation within these non-promoter regions in the pathogenesis of type 2 diabetes. This study suggests that DNA methylation within intergenic regions is a mechanism regulating microRNAs, another increasingly important epigenetic factor, during type 2 diabetesen_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/3.0/za/-
dc.subjectDNA methylationen_US
dc.subjectMicroRNAsen_US
dc.subjectType 2 diabetesen_US
dc.subjectPre-diabetesen_US
dc.subjectPromotersen_US
dc.subjectIntragenic regionsen_US
dc.subjectIntragenic regionsen_US
dc.titleDifferential DNA methylation of microRNAs within promoters, intergenic and intragenic regions of type 2 diabetic, pre-diabetic and non-diabetic individualsen_US
dc.type.patentArticleen_US
Appears in Collections:HWSci - Journal Articles (DHET subsidised)
Files in This Item:
File Description SizeFormat 
Pheiffer_Carmen_Erasmus_Rajiv_T_Kengne_Andre_P_Matsha_Tandi_E_Health & Well_2016.pdfMain Article419.7 kBAdobe PDFView/Open
Show simple item record

Page view(s)

64
Last Week
0
Last month
0
checked on Feb 9, 2021

Download(s)

63
checked on Feb 9, 2021

Google ScholarTM

Check


This item is licensed under a Creative Commons License Creative Commons